RedHill Biopharma Ltd – (RDHL) Expected to Post Quarterly Sales of $1.89 Million
Equities analysts expect RedHill Biopharma Ltd – (NASDAQ:RDHL) to post $1.89 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for RedHill Biopharma’s earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $1.98 million. RedHill Biopharma posted sales of $100,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 1,790%. The firm is scheduled to announce its next earnings report on Thursday, February 22nd.
On average, analysts expect that RedHill Biopharma will report full year sales of $1.89 million for the current year, with estimates ranging from $3.81 million to $3.98 million. For the next fiscal year, analysts forecast that the firm will report sales of $45.40 million per share, with estimates ranging from $8.80 million to $113.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that follow RedHill Biopharma.
RedHill Biopharma (NASDAQ:RDHL) last announced its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.18).
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up $0.05 on Wednesday, hitting $5.22. The stock had a trading volume of 142,200 shares, compared to its average volume of 138,680. RedHill Biopharma has a 12-month low of $4.30 and a 12-month high of $11.25. The company has a market capitalization of $111.04, a PE ratio of -1.93 and a beta of 1.01.
Several hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its position in shares of RedHill Biopharma by 13.6% in the second quarter. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,440 shares during the last quarter. Oppenheimer & Co. Inc. increased its position in shares of RedHill Biopharma by 10.8% in the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,500 shares during the last quarter. D.A. Davidson & CO. increased its position in shares of RedHill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Family Management Corp increased its position in shares of RedHill Biopharma by 51.5% in the second quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares during the last quarter. Institutional investors own 8.47% of the company’s stock.
About RedHill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.